Drive Wealth Management LLC Acquires New Holdings in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Drive Wealth Management LLC bought a new position in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 23,000 shares of the company’s stock, valued at approximately $916,000. Drive Wealth Management LLC owned 0.64% of Aligos Therapeutics as of its most recent filing with the SEC.

Separately, AlphaMark Advisors LLC raised its holdings in shares of Aligos Therapeutics by 1,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock worth $44,000 after acquiring an additional 1,000 shares during the period. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Stock Down 4.9 %

NASDAQ:ALGS opened at $30.43 on Monday. Aligos Therapeutics, Inc. has a twelve month low of $6.76 and a twelve month high of $46.80. The company has a market cap of $109.18 million, a P/E ratio of -2.28 and a beta of 2.50. The business has a 50 day moving average price of $32.24 and a two-hundred day moving average price of $18.86.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing the consensus estimate of ($2.15) by ($0.92). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The company had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.00 million. During the same period last year, the company posted ($10.25) earnings per share. As a group, analysts anticipate that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Aligos Therapeutics in a report on Thursday, November 7th.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).